Abstract Exhaled carbon monoxide (CO), which has been found to be elevated in asthma, is generated primarily by heme oxygenase 1 (HO-1), an enzyme induced by oxidant stress and cytokines.The aim of this study was to assess the distribution and expression of HO-1in various human lung cells in acute and stable asthma.
INTRODUCTION
Carbon monoxide (CO) is elevated in the exhaled air of asthma patients (1^4).This ¢nding is probably associated with the up-regulation of heme oxygenase-1 (HO-1), since previous studies have shown that total cellular CO is generated primarily via heme degradation by HO-1. (5^7). Immunoreactivity of HO-1has also been detected in the bronchial biopsies (8) and bronchoalveolar lavage £uid of asthma patients (1) .
The HO system consists of three proteins, an oxidative stress-induced form of the enzyme, called HO-1, and constitutive forms of the enzyme, all of which are products of distinct genes (7, 9) . Due to its molecular weight and rapid induction by heat and stress, HO-1 has been called heat shock protein 32 (5, 7, 10) . Heme oxygenase catalyses the rate-limiting step in the oxidative degradation of heme to biliverdin, a reaction which also releases CO and iron.
No systematic studies have been conducted on HO-1 expression or distribution in human lung tissue. A recent study on bronchial biopsies of segmental airways obtained by bronchoscopy showed a similar expression of HO-1 in healthy controls and asthmatics (8) . In our recent study on patients with sarcoidosis and interstitial pneumonia, however, HO-1was expressed only in alveolar macrophages (10) . Studies on rat lung have revealed HO-1 immunoreactivity in bronchial epithelium and in£ammatory cells of the airways after hyperoxia and in alveolar macrophages after hypoxia exposures (11, 12) . HO-1 expression has also been detected in human monocytes, where it is induced during erythrophagocytosis and cell activation (13, 14) . It is also known that HO-1 is stimulated not only by oxidants but also by endotoxin and in£ammatory cytokines (5,11,15^18) .
In this study, we ¢rst compared HO-1 expression in various cell types of human lung and in small and large airways using both para⁄n-embedded and frozen tissue samples.These studies con¢rmed our recent ¢ndings on HO-1expression mainly in alveolar macrophages.To better understand the regulation of HO-1 in asthma, we therefore assessed the expression of HO-1 in alveolar macrophages obtained by sputum induction from healthy subjects and asthma patients. The material included samples from healthy non-smoking individuals, recently diagnosed and untreated asthma patients, stable treated asthmatics and patients in the acute phase of asthma exacerbation under treatment. Furthermore, the time response of HO-1 was assessed in human monocytederived macrophages in culture.
METHODS

Lung tissue biopsies
The biopsy material of para⁄n-embedded tissues consisted of lung tissue samples from 6 subjects (5 non-smokers, one ex-smoker), all of whom had been operated on for a bronchial carcinoid tumour or malignancy (lung carcinoma, sarcoma or metastasis). The control subjects had no other diseases and no medication, their lung function was normal and the lung biopsies had been taken from areas with normal-looking histology. The biopsies were collected from the ¢les of the Department of Pathology, Oulu University Hospital.
Frozen tissue samples
Frozen tissue samples were obtained from additional 5 patients operated on for a lung tumour. The samples included central cartilage containing bronchus and, from one patient, peripheral lung tissue.
Induced sputum
Patients and processing of samples Induced sputum was obtained from 5 patients with recently diagnosed untreated asthma, 7 patients with stable asthma on inhaled corticosteroids and 5 asthmatics treated in hospital for asthma exacerbation with systemic steroids for at least 3 days before sputum sampling. The new and stable asthmatics were recruited from the outpatient clinic of Oulu University Hospital and the asthmatics with acute exacerbation from the pulmonary ward of the same hospital. All the patients were non-smokers. Forced expiratory £ow in 1sec (FEV1) varied within 63^124% of the reference value in the patients with asthma. The asthma diagnosis was based on reversible airway disease, as shown by a positive histamine or methacholine challenge test, a X15% increase in FEV1or PEF after the administration of an inhaled bronchodilator, or daily PEF variability X20%. The controls for the induced sputum group consisted of 6 healthy non-smoking individuals with normal spirometry ¢ndings and no history of asthma or other lung diseases (Table 1) .
Two patients with asthma exacerbation produced adequate sputum after inhalation of nebulised bronchodilators (salbutamol and ipratropium). In all other cases, sputum was induced by inhalation of 5 ml of 3% saline solution using an ultrasonic nebuliser (Omron U1, Omron, Germany). Both the healthy controls and the asthmatics were given 0?2 mg of salbutamol as dry powder inhalation15 min before the sputum induction. Peak expiratory £ow (PEF) values were measured before and after the induction to ensure the safety of the procedure.The subjects were asked to cough during and after the inhalation. Sputum was collected in a clean plastic container. If PEF decreased by more than 20% or subjective symptoms appeared, the patients were given 0?2 mg of inhaled salbutamol.
The sputum was processed by the method of Pizzichini and colleagues (19) . Sputum which was macroscopically free of salivary contamination was selected and treated with dithiotreitol (Sputolysin 10%, Calbiochem Corp., San Diego, CA, U.S.A.) and phosphate-bu¡ered saline. Five hundred micro litres of the ¢ltered suspension was used for the cell count and cytospin preparations. Only adequate samples with less than 80% squamous epithelial cell contamination from saliva (20) were accepted. In order to study the expression of HO-1in macrophages, additional cytospin preparations were ¢xed in acetone for 10 min.
Immunohistochemistry
The histological slides were immunostained as follows. The sections (4 mm) were depara⁄nised in xylene and dehydrated in graded ethanol.They were then incubated with 30% hydrogen peroxide in absolute methanol to consume the endogenous peroxidase. Background staining was minimised by treatment with 2% non-fat dry milk.The primary HO-1antibody (Transduction Laboratories, Lexington, KY, U.S.A.) was used in a dilution of 1:100, and the colour was developed with aminoethyl carbazole substrate solution (Zymed Laboratories). They were then incubated with the secondary antibody followed by HistostainTM-PLUS kit (Zymed Laboratories, South San Francisco, CA, U.S.A.). The colour was developed with aminoethyl carbazole (AEC) substrate solution (Zymed Laboratories). The sections were counterstained with a light haematoxylin stain.The negative controls consisted of PBS at pH 7?2 and the mouse serum isotype recommended by the manufacturer (Zymed Laboratories).
Cytospin slides were ¢xed in acetone for10 min and incubated with 8% hydrogen peroxide in water to consume the endogenous peroxidase. The background staining was minimised by treatment with 2% non-fat dry milk. The same primary HO-1 antibody as for histological slides was used in a dilution of 1:100.
The frozen sections were cut into 4 mm sections, ¢xed for 10 min in cold acetone and air-dried overnight. In order to consume endogenous peroxidase, the slides were incubated in 30% hydrogen peroxide in absolute methanol for 10 min. Non-speci¢c staining was blocked by incubating the slides in fetal calf serum. Primary antibody for HO-1 was then applied (dilution 1:100) to the slides for 60 min, followed by secondary anti-mouse antibody for 30 min, and the peroxidaseâ ntiperoxidase complex (Dako) for 30 min. The chromogen used was diaminobenzidine and the slides were then lightly counterstained with hematoxylin. HO-1 immunoreactivity was assessed semiquantitatively by two experienced lung pathologists independently and the interobserver repeatability was excellent (k=0?714). Immunoreactivity was graded as follows: À negative, + weak, ++ moderate, +++ strong and ++++ very strong. All analyses were conducted blindly without information about the clinical characteristics of the subjects.
Cell cultures and exposures
Monocytes were isolated from bu¡y coats (Finnish Red Cross Helsinki, Finland) using a modi¢ed method described by B˛ym (21) . The bu¡y coats were diluted with phosphate-bu¡ered saline (PBS), and the cell suspension was layered over Ficoll-Paque (Pharmacia, Biotech AB, Uppsala, Sweden) and centrifuged. Mononuclear cells were collected at the interface, washed with PBS and suspended in RPMI-1640 medium (Gibco Europe, Paisley, U.K.) supplemented with L-glutamine (Gibco), penicillinŝ treptomycin (Gibco) and 20% human serum (Finnish Red Cross). After isolation, the cells were incubated in collagen-coated (Vitrogen, Collagen-Corporation, Palo Alto, CA, U.S.A.) Petri dishes for 1h at 371C. After incubation, non-adherent cells were removed by washing with PBS. Adherent monocytes were cultured under 5% CO 2 at 371C for up to 72 h which has been shown to induce maturation of monocytes into monocyte-derived macrophages. The monocytes were exposed to formylated peptide fMLP (10 À7 M) (Sigma) or 100 and 500 mM H 2 O 2 for 24 or 72 h. FMLP is known to cause a respiratory burst of monocytes and macrophages, thereby mimicking oxidative stress in vivo.
Western blotting
The cell pellets were mixed with the electrophoresis sample bu¡er and boiled for 5 min at 951C. The protein concentration of the samples was measured using the Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA), and 75 mg of the cell protein was applied to 12% sodium dodecyl sulphate-polyacrylamide gels. The gels were electrophoresed for 1?5 h (90 V) at room temperature, and the protein was transferred (45 min,100 V) onto Hybond ECL nitrocellulose membranes (Amersham, Arlington Hights, IL, U.S.A.) in a Mini-PROTEAN II Cell (Bio-Rad). The blotted membranes were incubated with mouse antibody to HO-1 (diluted 1:250) followed by treatment with anti-mouse secondary antibody (diluted 1:2000) conjugated to horseradish peroxidase (Amersham). The reactivity was detected by an enhanced chemiluminescence system (ECL, Amersham), and the luminol excitation was imaged on X-ray ¢lm.
The study protocol was accepted by the ethical committee of the University of Oulu and Oulu University Hospital.
Statistical analysis
The statistical analyses were performed with SPSS for Windows software (SPSS, Chicago, IL, USA). The signi¢-cance of the associations was determined using Fisher's exact probability test designed for small sample groups. P-values of less than 0?05 were considered statistically signi¢cant.
RESULTS
Distribution and expression of HO-1 in the lung
The immunohistochemical reactivity of lung tissue was investigated in 6 non-smoking individuals with normal lung histology.With the exception of one case, all control lung biopsies showed strong HO-1 immunoreactivity in alveolar macrophages [ Fig.1(c) , Table 2 ].One biopsy from a subject with a carcinoid tumour showed no HO-1 immunoreactivity in any cells of the biopsy. Given the fact that HO-1 may show di¡erent expression patterns in the large and small airways, we also assessed HO-1 immunoreactivity in the large, cartilage-containing airways. However, even these samples were negative for HO-1 immunoreactivity.
Frozen lung samples from additional 5 patients were assessed for HO-1 immunoreactivity. These results showed no HO-1 reactivity in bronchial epithelium, but alveolar macrophages showed positive immunoreactivity.
Induced sputum
Macrophages in the induced sputum of non-smoking controls, with the exception of one case, showed no HO-1 immunoreactivity [ Table 1 and Fig. 1(a) ]. In induced sputum, HO-1 immunoreactivity appeared to be present more often in the macrophages of new asthmatics without inhaled anti-in£ammatory therapy (4/5) than in cases with stable asthma and inhaled anti-in£ammatory therapy (2/7) (P=0?027, Fisher's exact probability test) [ Table  1 and Fig. 1(b) ]. No HO-1 immunoreactivity could be detected in the sputum of asthmatics recovering from acute exacerbation who had been on systemic corticosteroid therapy for at least 3 days (P=0?023, Fisher's exact probability test).
Cell cultures
The time response of HO-1induction was investigated in cultured monocytes, which are known to maturate into macrophage-like cells in culture (22) . Monocytes showed scant expression of HO-1, which was enhanced by 500 mM H 2 O 2 and fMLP within the ¢rst 24 h of exposure. The induction was, however, only transient, since no elevated HO-1 expression could be detected after 72 h of exposure any more (Fig. 2) .
DISCUSSION
The present study shows that HO-1 is expressed in alveolar macrophages of human lung. It also appears that oxidant stress causes a rapid but transient induction of this enzyme in in£ammatory cells in vitro. These results are in line with the expression levels of HO-1 in vivo, since the present patient samples also showed a tendency towards higher HO-1 reactivity in the alveolar macrophages of untreated asthmatics but not in subjects with stable disease or after 72 h of treatment.
Tissue specimens obtained from surgical operations of non-smokers showed that HO-1 is expressed mainly in alveolar macrophages. This result does not exclude the possibility that small amounts of this enzyme could also be expressed in other cells of human lung since immunohistochemistry may not be sensitive enough to detect minor amounts of the enzyme protein.Our present ¢nd-ings are in agreement with our recent study on para⁄n-embedded biopsies of sarcoidosis and interstitial pneumonias (10) , which showed that HO-1 is expressed in macrophages. There is one recent study on bronchial biopsies obtained by bronchoscopy that investigated HO-1 immunoreactivity from frozen samples of segmental bronchial epithelium. In that study, similar positive HO-1 immunoreactivity was detected in the epithelium of healthy controls and asthmatic patients (8) . In view of inducibility of HO-1, however, bronchoscopy may cause induction of this enzyme both in healthy subjects and in asthmatics, and induction may also occur in healthy lung during surgery. In our study, additional stainings were also made on frozen lung biopsies, and even these results revealed immunoreactivity only in macrophages. Di¡er-ent levels of the bronchial tree may also show variable HO-1 immunoreactivity, but based on our ¢ndings, the large airways did not express HO-1, either. Thus, these additional studies did not change the overall conclusion that alveolar macrophages represent the cell population mainly responsible for HO-1 expression in human lung.
Degradation of heme by HO-1 generates CO, and exhaled CO has been suggested to be a sensitive marker of in£ammation in asthma (1, 9, 23) . The exhaled CO concentration has, however, been shown to be higher in Fig.1(c) ]. Fig.1(a) shows an induced sputum sample from a healthy control, (b) a sample from a newly diagnosed asthmatic without anti-in£ammatory treatment, and (c) a lung biopsy from a non-smoking patient.
atopic subjects than in non-atopic individuals (24) and similarly elevated in allergic rhinitis without asthma (25) . Exhaled CO is also elevated in respiratory infections (23, 26) and smokers (27) , which makes the interpretations of exhaled CO in asthma even more di⁄cult.The purpose of this study was not to investigate CO, but in agreement with the results on exhaled CO, our study showed HO-1 to be up-regulated in the alveolar macrophages of non-treated asthmatics, the immunoreactivity of HO-1also being higher in untreated than treated subjects with stable asthma. This is also consistent with the rapid inducibility of this enzyme and with the results on cultured monocytes showing transient up-regulation of HO-1 in oxidant-exposed cells.
In conclusion, our study shows that HO-1 is induced especially in the alveolar macrophages of human lung and that alveolar macrophages are probably the most important cell type to explain high CO in the exhaled air of asthma patients. Heme oxygenase may play a role in the acute in£ammation of human lung, but due to its rapid induction by oxidants, cytokines, infections and cigarette smoke, the speci¢city of HO-1 in the di¡erential diagnosis of asthma as well as in the clinical follow up of asthmatics appears to be modest. 
